Injection into mice of chimeric proteins consisting of a portion of either the simian virus 40 large tumor antigen or nonstructural protein 1 of influenza A virus or of the murine tumor suppressor p53 on one hand and T-cell epitopes of lymphocytic choriomeningitis virus on the other resulted in antiviral protective immunity, which was independent of the epitopes' position in the protein and the same whether the latter was immunologically nonself or self. Mice of different haplotypes were protected when the corresponding class I moleculerestricted epitopes had been inserted close to each other in one carrier protein.
Recently, we have described CD8
ϩ cell-mediated protective immunity against lymphocytic choriomeningitis (LCM) virus in BALB/c mice following the injection of a portion of either the viral nucleoprotein (NP) or the glycoprotein (GP-C) (32) . We now report that injection of chimeric products consisting of LCM virus-specific major histocompatibility complex class I molecule-restricted T-cell epitopes and proteins not related to LCM virus into BALB/c and also B6, CB6F1, and NMRI mice led to similar results.
(This work is part of the Ph.D. thesis of G. Weidt.) Specific-pathogen-free female BALB/c, C57BL/6 (B6), NMRI, CBA/J, C3H/HeJ, and [BALB/c ϫ C57BL/6] F 1 (CB6F1) mice were purchased from Charles River, Sulzfeld, Germany, and used when 8 to 12 weeks old. Strain WE LCM virus (29) was propagated and titrated as PFU in L cells (21). The derivation of NP 67-300 (amino acid residues [aa] 67 to 300 of the LCMviral NP) has been described previously (32) . The same method was employed to produce NS1 (aa 1 to 81 of nonstructural protein 1 of influenza A virus [NS-1]), TAg 2-270 (aa 2 to 270 of simian virus 40 [SV40] large tumor antigen [T-Ag]), and murine wild-type p53 (aa 2 to 387). The corresponding portions of cDNA coding for NP and GP-C of LCM virus (30), NS-1 (34), T-Ag (6), and p53 (17, 19) were cloned into pH6EX3 (4) and expressed in Escherichia coli. The proteins thus obtained are illustrated in Fig. 1 , where they have been designated N-0, S-0, T-0, and P-0, respectively.
The three LCM-viral CD8 ϩ T-cell epitopes included in this study were the following nonapeptides: aa 118 to 126 of NP, which is L d -restricted (31) , and aa 34 to 42 (14, 18) and aa 278 to 286 (26) of GP-C, which are D b restricted. Orthotopic exchange of T-cell epitopes in TAg 2-270 without altering flanking regions was achieved by PCR mutagenesis. The protein's coding sequence was amplified in two portions with two sets of primers, which were chosen such as to exclude the indigenous D b -restricted T-cell epitope, aa 207 to 215 (8, 13) . Instead, the two internal primers carried 27-bp-long extensions, one coding for the new T-cell epitope and the other being complementary to it. In a second step, both parts were annealed and extended by PCR, which was allowed to proceed without addition of primers. After amplification with outer primers by standard PCR, the altered DNA was cloned just as was the unmodified DNA, confirmed by sequencing, and expressed in E. coli; these proteins are designated T-1, T-3, and N-1 in Fig. 1 .
To place LCM-viral T-cell epitopes heterotopically into TAg 2-270 , NS1 1-81 , or p53, complementary oligonucleotides coding for an epitope and having cohesive ends were annealed and inserted into the corresponding restriction site of the vector. For positioning the epitope towards the protein's C-terminal end, the HindIII restriction site was used (T-2, T-4, P-1, P-2, and S-1 in Fig. 1) , and for positioning the epitope in the N-terminal region, the StyI restriction site was used (T-5 in Fig.  1 ). The same method was employed to insert two LCM-viral epitopes close to each other in the HindIII site of TAg 2-270 (T-6 in Fig. 1 ). All proteins thus synthesized contained additional amino acids on both ends, which were contributed by the vector (Fig. 1) .
These compounds were injected, together with sodium dodecyl sulfate, into mice, which were subsequently challenged with LCM virus; 5 days later, infectious titers in spleens were determined. The results of a representative experiment with BALB/c mice are summarized in Table 1 . Injection of TAg had no measurable effect on virus replication but resulted in immunity after an indigenous CD8 ϩ T-cell epitope had been exchanged with aa 118 to 126 of the LCM-viral NP. A similar degree of protection was obtained when the latter was inserted C terminally either alone or close together with a D b -restricted GP-C epitope, which, by itself, was ineffective in BALB/c mice. The murine p53, too, was protectively immunogenic when combined with aa 118 to 126 of NP. The capacity of NP 67-300 to induce antiviral immunity in BALB/c mice was lost by exchanging aa 118 to 126 with a D b -restricted epitope of GP-C. Corresponding results were obtained with B6 mice (Table 2) .
Injection of a chimeric protein consisting of the nonapeptide aa 118 to 126 of NP and TAg 2-270 resulted in protective immunity of CB6F1 (H-2 d/b ) mice (Table 3) pends on these cells (1, 32) . The data reported here provide evidence that protection is mediated exclusively by CD8 ϩ T lymphocytes. The immunogenic portions of our fusion proteins consisted of 9-aa-long established CD8 ϩ T-lymphocyte epitopes. Peptides that are recognized by CD4 ϩ cells are usually longer (reviewed in reference 12), and overlapping of CD8 ϩ and CD4 ϩ T-cell epitopes, which has been described previously (24, 27), does not seem to occur often.
Epitope-specific immunity has previously been achieved by the use of ''minigenes'' (2, 3, 9, 10, 33), whose mode of action, however, is principally different. Minigenes are not immunogenic by themselves but have to be expressed. Moreover, most minigenes that have been described are embedded in viral genomes and capable of replication. In general, they require the transcribing and translating machinery of a cell; hence, immunization with a minigene is not much different from immunization with an infectious virus. Consequently, processing of epitopes and their subsequent presentation presumably occur in the cytosole. Chimeric proteins, on the other hand, are directly immunogenic and cannot replicate; the pathway the epitopes take for being presented by cells is currently not known.
According to the present findings, injection of a protein carrying closely spaced epitopes of different haplotypes results in protection of mice belonging to these haplotypes. Furthermore, immunity was evoked in mice of different haplotypes injected with a fusion protein containing only one epitope. Vaccinia virus recombinants carrying minigenes encoding CD8 ϩ T-cell epitopes have previously been shown to be immunogenic when the latter were arranged close to each other (3, 33) . Again with a vaccinia virus recombinant encoding aa 1 to 201 of the LCM-viral NP, cross-protection has been achieved against LCM virus in mice belonging to three different haplotypes, namely, H- The observation that p53, which is immunologically self, may carry an immunogenic epitope was not a priori self-evident. True, in the absence of nonself proteins, class I molecules are loaded with self peptides (reviewed in reference 28), which are excised from indigenous cellular proteins in probably much the same way as are immunologically active peptides from, for instance, viral proteins. Our findings show that self molecules, which have to be taken up by antigen-presenting cells, can be processed and presented with similar results. Zaghouani and his colleagues (35) had demonstrated that cells transfected with a murine immunoglobulin heavy-chain gene in which the CDR3 loop carried a class I molecule-restricted influenza virus epitope specifically activated cloned cytotoxic T lymphocytes.
The question as to how proteins are fragmented to portions of correct lengths in order to be accepted by class I molecules is currently unanswered. Surely, proteases are involved, the identification of which might be furthered if cleavage sites were known, but while there are observations indicating that amino acid sequences in the epitopes' neighborhood have some in- fluence (3, 9, 11, 16) , other findings attest to the contrary (references 2, 7, 13, 15, and 35 and this report). The interpretation of these different findings is difficult because of the fact that in most of the experiments, target cells for cytotoxic T lymphocytes were analyzed rather than proper antigen-presenting cells, meaning cells that initiate in vivo the immunologic induction phase. However, equally divergent results were obtained when vaccinia virus recombinants carrying minigenes encoding CD8 ϩ T-cell epitopes were employed to immunize mice, and the picture becomes even more complex when these results are contrasted with what has been observed when the same recombinants were used to prepare target cells in vitro (3, 9, 33) . We find that nonameric LCM-viral CD8 ϩ T-cell epitopes, as parts of proteins that are not related to LCM virus, may induce anti-infectious immunity independently of the position they hold.
